ENDRA Life Sciences reports Q2 preliminary: no revenue, operating loss $1.3M

ENDRA Life Sciences Inc.

No revenue for quarter ended June 30, 2025; same as Q2 2024 with zero revenue.
Expected operating loss of ~$1.3M, improved from ~$2.2M loss in Q2 2024.
As of June 30, 2025: cash and equivalents $1.8M; total assets $2.6M; working capital $1.2M.
Firm filed S-1 registration statement to offer shares and warrants in a public offering.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.